The ASH Education Program will be held from Saturday, December 1, through Monday, December 3, with most sessions being offered twice. A question-and-answer period will occur at the end of each individual speaker presentation.
Chapters based on these sessions will be published in Hematology 2018, the ASH Education Program.
Mark A. Crowther, MDSt. Joseph's Hospital, Hamilton, Canada
Mikkael A. Sekeres, MDCleveland Clinic Taussig Cancer Center, Cleveland, OH
Jump to:
(Select) A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphocytic Leukemia Acute Myeloid Leukemia: Moving Beyond 7+3 Aggressive Lymphomas Approach to the Treatment of the Older, Unfit Patient With Myeloma: From Diagnosis to Relapse Approach to the Treatment of the Young, Fit Patient With Myeloma: From Diagnosis to Relapse As If Myeloproliferative Neoplasms Weren't Already Challenging Enough AYA: Big Children or Small Adults? Leukemia Treatment in Adolescence Chronic Myeloid Leukemia: With Great Success Comes Great Responsibility Follicular Lymphoma: Have We Made Progress? Hodgkin Lymphoma: Beyond ABVD for Everyone Reining in Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation The Future of Chronic Lymphocytic Leukemia (CLL) Therapy The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) Update in Transfusion Therapy for Hematologic Malignancies: Transfusion Support TACO and TRALI Using Genomics to Risk Stratify and Treat Kids Anxiety-Provoking Consults: Macrophage Activation Syndrome, Castleman Disease, and Hypereosinophilia Delivering High-Quality Oral Anticoagulant Therapy: State of the Art in 2018 Hemolytic Anemia: A Cornucopia of Causes Hemostatic and Thromboembolic Challenges in the Young High-Performance Hematology: Elite Athletes and Weekend Warriors Junior Faculty Career-Development Session Long-Term Management of VTE: The First Six Months and Beyond Severe Aplastic Anemia: Diagnosis and Management in an Era of Effective Therapies Sickle Cell Disease: New Frontiers Thalassemia Syndromes: Diagnosis and Management in a Changing World The Interface Between Man and Machine: Managing Hemostasis and Thrombosis in the Plastic and Metal Circulation Thrombotic Thrombocytopenic Purpura (TTP) 2019: State of the Art What's Hot in Immune Thrombocytopenic Purpura (ITP)?
Dr. Michaela Liedtke will discuss monoclonal and bi-specific antibodies including rituximab, inotuzumab ozogamicin and blinatumomab. She will highlight key differences in their mechanism of action and provide an overview of clinical trial results that support their use. Dr. Liedtke will summarize current recommendations and review ongoing clinical studies using antibody-based ALL therapy.
Dr. Michael Pulsipher will review the role of CAR T-cell therapy in ALL and compare this approach with hematopoietic stem cell transplant. CAR T-cell therapy is still early in its development, and Dr. Pulsipher will describe how different CAR T-cell constructs can be used safely and optimally. He will then summarize practical issues associated with successfully getting patients to this therapy, and project how CAR T cells fit into our treatment paradigms now and going forward.
Dr. Mark Litzow will review some of the major toxicities that have arisen in the setting of the new immunotherapies that are revolutionizing the treatment of ALL. He will discuss how these toxicities need to be accounted for as clinicians plan the overall management of their patients. The financial burden of these new immunotherapies will be discussed and placed in the context of the benefits these therapies bring to patients.
MichaelaLiedtke,MDStanford Cancer InstituteStanford,CA
MichaelaLiedtke,MDStanford Cancer InstituteStanford,CAAntibody-Based Therapies in Patients With ALL
Michael A.Pulsipher,MDChildren's Hospital Los AngelesLos Angeles,CAAre CAR T Cells Better Than Antibody or Hematopoietic Cell Transplantation (HCT) Therapy in ALL?
Mark R.Litzow,MDMayo ClinicRochester,MNNo Free Rides: Management of Toxicities (Including Financial) of Novel Therapies in ALL
Dr. Elizabeth Griffiths will review the role of mutational profiling in helping to define disease biology in AML at diagnosis and relapse. She will describe how mutational data are helping to inform clinical prognosis and provide opportunities for rational targeted therapeutics. Dr. Griffiths will further review which mutational events might be used to alter the approach to patient care by distinguishing those patients likely to benefit from traditional consolidation from those more suitable for inclusion in clinical trials or upfront allogeneic transplantation.
Dr. Daniel Pollyea will discuss what approaches to AML may look like in the near future with newer, molecularly defined therapies that may complement, or replace, intensive induction chemotherapy. He will describe which agents are most promising, when and how they may be used, and outline an approach to AML informed by disease biology rather than convention.
Dr. Laura Michaelis will discuss the role that classical cytotoxic therapy still plays in the treatment of newly diagnosed and relapsed patients with AML. She will summarize what can be expected from cytotoxic induction regimens in patients with good risk and intermediate risk disease and update the audience on options for patients with adverse risk cytogenetic and molecular features. Dr. Michaelis will touch on new developments in relapsed/refractory disease and, finally, will outline a reasonable approach to choosing which patients are least likely to benefit from cytotoxic therapy and should be targeted for clinical trials of less-intensive options.
Laura C.Michaelis,MDMedical College of WisconsinMilwaukee,WI
Elizabeth A.Griffiths,MDRoswell Park Comprehensive Cancer CenterBuffalo,NYWhen to Obtain Genomic Data in AML and Which Mutations Matter
Daniel APollyea,MDUniversity of ColoradoAurora,CONew Drugs Inspired by Genomics and When to Use Them
Laura C.Michaelis,MDMedical College of WisconsinMilwaukee,WICytotoxic Therapy in AML: Not Quite Dead Yet
Dr. David Weinstock will discuss recent advances in our understanding of the pathobiology of T-cell lymphomas, focusing on genetic alterations with diagnostic, prognostic or therapeutic relevance. He will review issues that have complicated the development of precision medicine for patients with T-cell lymphomas and discuss newer approaches for extending genomic, transcriptional and phenotypic platforms for disease assessment.
Dr. Lisa Rimsza will discuss genomic abnormalities in B-cell lymphoma. This talk will cover disease-defining abnormalities including high grade B cell lymphomas with MYC and BCL2 and/or BCL6 translocations, RNA expression patterns in diffuse large B-cell lymphoma, key gene amplifications, prognostic and predictive mutations, and clonal heterogeneity.
Dr. Jonathon Cohen will discuss the development of novel therapies in the management of relapsed/refractory lymphoma. He will review the most promising classes of agents including targeted therapies, antibody-drug conjugates, and cellular therapies, and will review the role of molecular diagnostics in therapy selection.
Lisa M.Rimsza,MDMayo Clinic - ScottsdaleScottsdale,AZ
David MWeinstock,MDDana Farber Cancer InstituteBoston,MAT Cell Lymphomas: Advances in Genomics and Classification
Lisa M.Rimsza,MDMayo ClinicScottsdale,AZB Cell Lymphomas: Advances in Genomics and Classification
Jonathon B.Cohen,MD,MSWinship Cancer Institute of Emory UniversityAtlanta,GANovel Therapies for Relapsed/Refractory Aggressive Lymphomas
Drs. Thierry Facon and Tanya Wildes will use a case of newly diagnosed MM in an older patient to discuss the international and North American viewpoints, respectively, regarding diagnostic, prognostic, and treatment options. The speakers will highlight the utility of patient related factors (e.g., frailty) and tumor related factors (e.g., high risk genetics) informing choice of initial therapy, management of bone disease, use of maintenance therapy, and treatment options for relapsed disease. In this time of rapid advances, this session describes how North American and international experts treat MM to optimize response and quality of life, decrease adverse events, and prolong PFS and OS.
Kenneth C.Anderson,MDJerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical SchoolBoston,MA
ThierryFacon,MDHpital Claude HuriezLille,FranceTreatment Perspective 1
TanyaWildes,MDWashington UniversitySaint Louis,MOTreatment Perspective 2
EricSeifter,MDJohns Hopkins University School of MedicineBaltimore,MD
Saad Z.Usmani,MDLevine Cancer InstituteCharlotte,NCTreatment Perspective 1
Sergio A.Giralt,MDMemorial Sloan Kettering Cancer CenterNew York,NYTreatment Perspective 2
Dr. Ann Mullally will discuss the molecular genetics of MPNs, encompassing both phenotypic driver mutations (JAK2, CALR, MPL) and concomitant high-risk mutations such as ASXL1. She will describe the biology of these mutations and their implications for both prognosis and treatment. Dr. Mullally will also review risk stratification in MPNs more broadly, focusing on recently published models which integrate clinical and molecular variables.
Dr. Ruben Mesa will discuss management of advanced phase MPNs. He will review what constitutes progression, including transformation to acute leukemia. Dr. Mesa will summarize the challenges related to defining resistance and/or intolerance to JAK inhibitors (e.g., ruxolitinib), and management strategies for these patients. Treatment options for accelerated and blast phase disease will be outlined, including both those with and those without a transplant option.
Dr. Jason Gotlib will highlight the challenges related to diagnosis and classification of advanced variants of systemic mastocytosis (advSM). He will review the treatment landscape of KIT inhibition in advSM, including selective KIT D816V inhibitors in clinical trials. Dr. Gotlib will summarize clinical and molecular markers for monitoring response and progression, and will outline a roadmap for addressing the unmet needs of advSM patients.
Jason R.Gotlib,MD,MSStanford Cancer InstituteStanford,CA
AnnMullally,MDBrigham and Women's HospitalBoston,MAJAK2 (and Other Genes): Be Nimble With MPN Diagnosis, Prognosis, and Therapy
Ruben A.Mesa,MD, FACPMays Cancer Center at UT Health San AntonioSan Antonio,TXAdvancing Treatments for Advanced Phase MPNs
Jason R.Gotlib,MD,MSStanford Cancer InstituteStanford,CAThe New Tool KIT in Advanced Systemic Mastocytosis
Dr. Kathryn Roberts will summarize recent advances in the genomic profiling of children, AYAs and older adults, and will compare differences in the genomic landscape that may contribute to poor outcome. She will also discuss the identification of new genetic subgroups and their implications for treatment, including Ph-like acute lymphocytic leukemia.
Dr. K. Scott Baker will discuss survivorship issues unique to the AYA population including the physical, social and emotional needs that differ not only from their peers, but also from the needs of younger or older cancer survivors.
Dr. Theresa Keegan will present recent patterns in AYA clinical trial enrollment, will consider variations in enrollment across cancer types, and will discuss barriers and facilitators to clinical trial participation including sociodemographic and treatment-setting characteristics.
Kathryn G.Roberts,PhDSt. Jude Children's Research HospitalMemphis,TN
Kathryn G.Roberts,PhDSt. Jude Children's Research HospitalMemphis,TNGenetics and Prognosis in Children Versus Adults
K. ScottBaker,MD, MSFred Hutchinson Cancer Research CenterSeattle,WALong-Term Complications in Adolescent and Young Adult (AYA) Leukemia Survivors
Theresa H.M.Keegan,PhD, MSUniversity of California DavisSacramento,CAAdolescent Angst: Enrollment in Clinical Trials
Jane Apperley will describe the outcome of newly diagnosed patients newly treated with first or second generation TKIs, discuss the balance between the desire to achieve the deep molecular responses that permit trials of TKI discontinuation and the potential adverse effects of the early use of the more potent TKIs, and provide pragmatic advice regarding treatment decisions.
Tim Hughes will explore the appropriate time-dependent molecular targets for CML patients on TKI and the reasons why those targets differ, especially when considering treatment discontinuation. He will discuss the factors that influence the choice of TKI when molecular responses are not optimal and will highlight the critical role of molecular monitoring in managing treatment-free remission.
Charles Craddock will summarise the results of alloSCT in all phases of CML and discuss factors affecting decision-making now that increased donor availability and reduced intensity conditioning regimens have increased the number of transplant eligible patients. As disease relapse remains a major cause of treatment failure he will focus on emerging peri and post-transplant strategies to improve outcome.
JaneApperley,MB ChB MDImperial College LondonLondon,United Kingdom
JaneApperley,MB ChB MDImperial College LondonLondon,United KingdomThe Argument for Using Imatinib in CML
Timothy P.Hughes,MDSouth Australian Health and Medical Research InstituteAdelaide,AustraliaMolecular Monitoring in CML: How Deep, How Often, and How Should It Influence Therapy?
CharlesCraddock,FRCP, FRCPathQueen Elizabeth HospitalBirmingham,United KingdomWe Do Still Transplant CML, Don't We?
Dr. John P. Leonard will discuss new developments in the first line management of FL. He will address approaches to risk stratify patients, indications for treatment, and options for first line therapy. Dr. Leonard will present the risks and benefits for first line single agent therapy, immunomodulatory drugs with rituximab, chemoimmunotherapy, and maintenance rituximab.
Dr. Christopher Flowers will discuss treatment options for patients with relapsed FL. He will address strategies for sequencing of therapy in the management of relapsed patients and personalized approaches for balancing patient characteristics, preferences, and comorbidities with treatment-related factors such as efficacy, toxicity profile, and mechanisms of action to optimize outcomes.
Dr. Loretta Nastoupil will discuss current approaches using immune-based therapies for patients with FL and the biological rationale for future strategies. She will address ongoing and emerging clinical trials using novel immunotherapy approaches aimed at improving outcomes.
Christopher RFlowers,MD,MSWinship Cancer Institute of Emory UniversityAtlanta,GA
John P.Leonard,MDWeill Cornell Medical College/The NewYork-Presbyterian HospitalNew York,NYWhere to Start? Upfront Therapy for Follicular Lymphoma in 2018
Christopher RFlowers,MD,MSWinship Cancer Institute of Emory UniversityAtlanta,GANovel Immunotherapy Approaches to Follicular Lymphoma
Loretta J.Nastoupil,MDThe University of Texas MD Anderson Cancer CenterHouston,TXSequencing of Therapies in Relapsed Follicular Lymphoma
Dr. Ranjana Advani will summarize recent advances in the frontline treatment of advanced-stage Hodgkin lymphoma. She will discuss response-adapted therapy and the role of novel agents in patients with newly diagnosed advanced stage disease.
Dr. Alison Moskowitz will discuss the ideal settings for use of brentuximab vedotin in Hodgkin lymphoma. She will review the data supporting approved and investigational uses.
Dr. Alex Herrera will discuss the role of PD-1 inhibitors in the treatment of Hodgkin lymphoma. He will review the data supporting approved indications for PD-1 blockade and discuss investigational combinations.
Alison J.Moskowitz,MDMemorial Sloan Kettering Cancer CenterNew York,NY
Ranjana H.Advani,MDStanford Cancer CenterStanford,CARisk-Adapted Upfront Therapy for Hodgkin Lymphoma in 2018
Alison J.Moskowitz,MDMemorial Sloan Kettering Cancer CenterNew York,NYOptimizing the Role of Brentuximab in Hodgkin Lymphoma Therapy
Alex F.Herrera,MDCity of HopeDuarte,CAWhere Do PD-1 Inhibitors Fit in Hodgkin Lymphoma Therapy?
Dr. James Ferraras talk will deal with the biology of GVHD in the intestinal tract which is the most difficult organ to treat. The ability of serum biomarkers that predict long term GVHD outcomes, which relate primarily to the intestinal tract, will also be discussed, including new biologic insights offered by the biomarkers.
Dr. Betty Hamilton will summarize the current strategies to prevent and treat GVHD in alloHCT. She will discuss the limitations and challenges to these approaches and focus on the review of novel prophylactic strategies under development and used in clinical trials for the prevention of GVHD.
Dr. Robert Zeiser will discuss novel therapeutic strategies to treat GVHD with a focus on kinase inhibition. He will also summarize features of the pathomechanism of acute GVHD and strategies that target pathways involved in immune cell activation. Dr. Zeiser will also review kinase inhibition strategies that could enhance graft-versus-leukemia effects.
RobertZeiser,MDUniversity of Freiburg Medical CenterFreiburg,Germany
James L.Ferrara,MD,DScIcahn School of Medicine at Mount SinaiNew York,NYWhat Causes Graft-Versus-Host Disease? Biology Matters
Betty K.Hamilton,MDCleveland Clinic FoundationCleveland,OHCurrent Approaches to Prevent and Treat GVHD Following Allogeneic Stem Cell Transplantation
RobertZeiser,MDUniversity of Freiburg Medical CenterFreiburg,GermanyInnovative Approaches to Treat GVHD Following Allogeneic Stem Cell Transplantation
Dr. Nitin Jain will review the risk-stratified frontline therapy of fit and unfit CLL patients in current practice, including the important considerations influencing that choice. He will further discuss the potential implications of ongoing clinical trials that are incorporating novel agents in frontline therapy.
Dr. Jennifer Brown will discuss relapsed therapy with a focus on sequencing in clinical practice, including the management of patients progressing on BTK inhibitors, as well as combination therapies in development and newer agents that may alter the treatment landscape. She will further discuss some of the theoretical considerations and unknowns in this rapidly evolving field.
Dr. Wei Ding will review and discuss the current data on Richter transformation, its biology and therapy in the era prior to novel agents, and whether and how its manifestations are changing in the era of novel agents.
Jennifer R.Brown,MD, PhDDana-Farber Cancer InstituteBoston,MA
NitinJain,MDMD Anderson Cancer CenterHouston,TXSelecting Frontline Therapy for CLL in 2018
Jennifer R.Brown,MD, PhDDana-Farber Cancer InstituteBoston,MARelapsed CLL: Sequencing, Combinations, and Novel Agents
WeiDing,MD, PhDMayo ClinicRochester,MNRichter Transformation in the Era of Novel Agents
Dr. David Steensma will review the clinical challenge of the common aging-associated neoplasm precursor state of clonal hematopoiesis of indeterminate potential (CHIP), including potential mechanisms of clonal progression to MDS or other hematological neoplasms, as well as risk of cardiovascular events due to circulating clonally-derived monocytes. He will also discuss management of patients with CHIP.
Dr. Aziz Nazha will review established prognostic models in MDS and their strengths and weaknesses when applied in clinical practice. He will also discuss the prognostic impact of somatic mutations in MDS, the addition of these mutations to current models, and newer approaches of incorporating the clinical and mutational data into novel prognostic models.
Dr. Amy DeZern will discuss recent developments in molecular characterization of MDS, which are improving diagnostic accuracy, providing insights into pathogenesis, and refining treatment options. She will summarize the status of our biologic knowledge of the mutational profiles in this heterogenous disease. Dr. DeZern will then outline optimal strategies for therapeutic management and highlight the current potential and challenges for targeting molecular mutations in patients with MDS.
David P.Steensma,MDDana-Farber Cancer InstituteBoston,MA
David P.Steensma,MDDana-Farber Cancer InstituteBoston,MAHow CHIP Flips Into MDS
AzizNazhaCleveland ClinicCleveland,OHThe MDS Genomics-Prognosis Symbiosis
Amy E.DeZern,MDThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore,MDTreatments Targeting MDS Genetics: A Fool's Errand?
Dr. Christine Cserti-Gazdewich will focus her presentation on inconsistencies and gaps in care as they relate to the two-dimensional theme of quantity and quality of our blood ordering, particularly as it relates to red blood cells. She will address blood compatibility testing, matching logistics in hematological malignancies and the most common hazards and impacts that are cumulatively peculiar to hematological malignancies.
Dr. Nadine Shehata will discuss managing patients who are refractory to platelet transfusions. She will address platelet refractoriness, its causes and clinical significance. Dr. Shehata will also present non-immune mediated platelet refractoriness. Finally, she will provide clinically relevant information and suggest approaches to caring for patients with platelet refractoriness. The practicing hematologist will find this presentation highly relevant to daily challenges.
Dr. Nareg Roubinian will discuss pathophysiology of transfusion associated circulatory overload (TACO) and transfusion related acute lung injury (TRALI) based on recent data from in vivo models and clinical investigations. He will present transfusion and recipient risk factors for TACO and TRALI with an emphasis on patients with hematological malignancies. Dr. Roubinian will update the audience on contemporary incidence and prevention of these transfusion complications.
ZbigniewSzczepiorkowski,MD, PhDDartmouth-Hitchcock Medical CenterLebanon,NH
Christine M.Cserti-Gazdewich,BSc, MD, FRCPCUniversity Health Network, University of TorontoToronto,ON,CanadaShifting Ground and Gaps in Transfusion Support of Patients With Hematologic Malignancies
NadineShehata,MD,FRCPC,MScMount Sinai HospitalToronto,ON,CanadaManaging the Patient: Refractory to Platelets
NaregRoubinian,MDUniversity of California San FranciscoSan Francisco,CATACO and TRALI: Biology and Current Therapy
Dr. Charlotte Niemeyer will review the genetics and approaches to risk stratification of patients with juvenile myelomonocytic leukemia (JMML). She will also discuss the common congenital syndromes that can be associated with JMML, such as Noonan syndrome and neurofibromatosis type 1, along with the complexities of managing such patients when they develop JMML.
Dr. Mignon Loh will review the broad landscape of somatic genetics of childhood acute lymphocytic leukemia and acute myeloid leukemia and will discuss how risk stratification has been influenced by these alterations. She will also present examples of how targeted therapies have been introduced for relevant patients.
Using a case-based approach, Dr. Eric Kodish will review dilemmas raised by genomic testing from the perspective of pediatric ethics. Issues discussed will include but not be limited to parental permission, assent, informed consent, incidental findings, research ethics, and managing uncertainty.
View original post here:
Education Program - The American Society of Hematology